Compare Merck & Co., Inc. (MRK) vs abrdn Physical Palladium Shares ETF (PALL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs abrdn Physical Palladium Shares ETF — how do they compare? Merck & Co., Inc. trades at $148.15 (market cap $366.28B), while abrdn Physical Palladium Shares ETF trades at $24.5. The key difference: Merck & Co., Inc. pays a 2.29% dividend while abrdn Physical Palladium Shares ETF pays none, and Merck & Co., Inc. is trading nearer its 52-week high, abrdn Physical Palladium Shares ETF nearer its low. Which is the better fit depends on your goals.
| MRK | PALL | |
|---|---|---|
Market Cap | $366.28B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $156.43 | $37.18 |
52-Week Low | $77.60 | $20.97 |
Enterprise Value | $413.04B | — |
Dividend Yield | 2.29% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $148.49, down 1.23% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $156.71. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending, and maintains a robust gross profit margin of 72.97%. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives amid a competitive pharmaceutical landscape.
The outlook for MRK is positive, driven by earnings momentum and strategic acquisitions, but risks include high valuation multiples like a P/E of 118.77 and regulatory pressures. Investors should weigh the company's solid cash flow and analyst support against potential market volatility and integration challenges from recent M&A activity.
PALL, the Aberdeen Physical Palladium Shares ETF, trades at $24.43, down 3.48% over 24 hours. Technical indicators are bearish, with moving averages signaling sell pressure, while oscillators are neutral. Recent news highlights palladium's underperformance relative to other precious metals, with some analysts viewing current price weakness as a potential buying opportunity due to supply risks and industrial demand.
The outlook for PALL hinges on palladium's supply-demand dynamics and broader commodity trends. Investment opportunities exist if palladium prices rebound from support levels, but risks include continued commodity volatility and macroeconomic pressures affecting industrial demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About abrdn Physical Palladium Shares ETF
PALL is a physically-backed ETF that tracks the spot price of palladium. It holds physical bullion in secure vaults, offering a liquid way to invest in this precious metal primarily used in automotive catalytic converters and electronics.
Read more on PALL →
